These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38320737)

  • 1. IKAROS gain of function disease: Allogeneic hematopoietic cell transplantation experience and expanded clinical phenotypes.
    Klangkalya N; Stoddard J; Niemela J; Sponaugle J; Greenwell IB; Reigh E; Kuehn HS; Kanakry JA; Rosenzweig SD; Dimitrova D
    Clin Immunol; 2024 Mar; 260():109922. PubMed ID: 38320737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss-of-phosphorylation of IKZF1 results in gain-of-function associated with immune dysregulation.
    Hoshino A; Picard BH; Polychronopoulou S; Kelaidi C; Azarnoush S; Kracker S; Rieux-Laucat F; Boutboul D; Latour S
    J Allergy Clin Immunol; 2024 Jul; 154(1):229-236.e2. PubMed ID: 38438084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgG4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant.
    García-Solís B; Tapia-Torres M; García-Soidán A; Hernández-Brito E; Martínez-Saavedra MT; Lorenzo-Salazar JM; García-Hernández S; Van Den Rym A; Mayani K; Govantes-Rodríguez JV; Gervais A; Bastard P; Puel A; Casanova JL; Flores C; Pérez de Diego R; Rodríguez-Gallego C
    J Allergy Clin Immunol; 2024 Sep; 154(3):819-826. PubMed ID: 38579942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inborn errors of human IKAROS: LOF and GOF variants associated with primary immunodeficiency.
    Kuehn HS; Boast B; Rosenzweig SD
    Clin Exp Immunol; 2023 Apr; 212(2):129-136. PubMed ID: 36433803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.
    Kuehn HS; Nunes-Santos CJ; Rosenzweig SD
    J Clin Immunol; 2021 Jan; 41(1):1-10. PubMed ID: 33392855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations.
    Leiding JW; Okada S; Hagin D; Abinun M; Shcherbina A; Balashov DN; Kim VHD; Ovadia A; Guthery SL; Pulsipher M; Lilic D; Devlin LA; Christie S; Depner M; Fuchs S; van Royen-Kerkhof A; Lindemans C; Petrovic A; Sullivan KE; Bunin N; Kilic SS; Arpaci F; Calle-Martin O; Martinez-Martinez L; Aldave JC; Kobayashi M; Ohkawa T; Imai K; Iguchi A; Roifman CM; Gennery AR; Slatter M; Ochs HD; Morio T; Torgerson TR;
    J Allergy Clin Immunol; 2018 Feb; 141(2):704-717.e5. PubMed ID: 28601685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Socié G; Beauvais D; Klein S; Wagner-Drouet EM; Blaise D; Nguyen-Quoc S; Bourhis JH; Thiebaut A; Labussière-Wallet H; Charbonnier A; Berceanu A; Diez-Martin JL; Fegueux N; Esteve J; Nagler A; Mohty M
    Bone Marrow Transplant; 2021 May; 56(5):1047-1055. PubMed ID: 33235351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations.
    Hoshino A; Okada S; Yoshida K; Nishida N; Okuno Y; Ueno H; Yamashita M; Okano T; Tsumura M; Nishimura S; Sakata S; Kobayashi M; Nakamura H; Kamizono J; Mitsui-Sekinaka K; Ichimura T; Ohga S; Nakazawa Y; Takagi M; Imai K; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Kojima S; Nonoyama S; Morio T; Kanegane H
    J Allergy Clin Immunol; 2017 Jul; 140(1):223-231. PubMed ID: 27939403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple functions of Ikaros in hematological malignancies, solid tumor and autoimmune diseases.
    Chen Q; Shi Y; Chen Y; Ji T; Li Y; Yu L
    Gene; 2019 Feb; 684():47-52. PubMed ID: 30352248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Tang S; Shen H; Qu C; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
    Bone Marrow Transplant; 2019 Feb; 54(2):236-243. PubMed ID: 29942002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline
    Kuehn HS; Nunes-Santos CJ; Rosenzweig SD
    Expert Rev Clin Immunol; 2021 Apr; 17(4):407-416. PubMed ID: 33691560
    [No Abstract]   [Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations.
    Kellner ES; Krupski C; Kuehn HS; Rosenzweig SD; Yoshida N; Kojima S; Boutboul D; Latour S; Barlogis V; Galambrun C; Stray-Pedersen A; Erichsen HC; Marsh RA
    J Allergy Clin Immunol; 2019 Jul; 144(1):339-342. PubMed ID: 30965037
    [No Abstract]   [Full Text] [Related]  

  • 15. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
    Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
    Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
    Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
    J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
    Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditioning regimens for inborn errors of immunity: current perspectives and future strategies.
    Nishimura A; Miyamoto S; Imai K; Morio T
    Int J Hematol; 2022 Jul; 116(1):7-15. PubMed ID: 35675025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storer BE; Guthrie KA; Schoch HG; Maloney DG; Sandmaier BM; Storb R
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):105-12. PubMed ID: 25278458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.